Alnylam Pharmaceuticals
ALNY
#549
Rank
A$64.29 B
Marketcap
A$486.64
Share price
-2.52%
Change (1 day)
8.91%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): A$0.18 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$3.21 Billion. In 2024 the company made an earning of -A$0.34 Billion, an increase over its 2023 earnings that were of -A$0.45 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) A$0.18 B-153.74%
2024 -A$0.34 Billion-24.59%
2023 -A$0.45 Billion-67.84%
2022 -A$1.4 Billion36.93%
2021 -A$1.03 Billion-8.04%
2020 -A$1.12 Billion-15.66%
2019 -A$1.32 Billion12.23%
2018 -A$1.18 Billion62.91%
2017 -A$0.72 Billion17.78%
2016 -A$0.62 Billion43.44%
2015 -A$0.43 Billion60.69%
2014 -A$0.27 Billion98.2%
2013 -A$0.14 Billion
2011 -A$78.92 Million27.48%
2010 -A$61.9 Million-10.92%
2009 -A$69.49 Million95.77%
2008 -A$35.5 Million
2006 -A$56.87 Million-9.13%
2005 -A$62.58 Million34.74%
2004 -A$46.45 Million36.79%
2003 -A$33.96 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
A$23.63 B 12,499.18%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$13.09 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$7.40 B 3,848.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-A$0.37 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-A$68.28 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-A$0.23 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$2.55 B 1,259.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$0.20 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA